RxDoctor Payments Data

Sherri Hansen, MD

Psychiatry · Madison, WINPI 1730195736

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.3% of the total across 164 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 13.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,365 and has fallen 92.4% since, to $104 in 2024.

$2,492in general payments, 2019–2025

Across 164 payments — averaging $15.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lundbeck LLC$326
  • Takeda Pharmaceuticals U.S.A., Inc.$301
  • AbbVie$237
  • Otsuka America Pharmaceutical, Inc.$198
  • Shire North American Group Inc$170
  • Neos Therapeutics, LP$164
  • plus $1K from 20 others

What the payments were for

  • Food & beverage$2,47699%
  • Education$171%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,492 in reported general payments places this provider in the 85th percentile of 543 psychiatry providers in Wisconsin.

See all psychiatry providers in Wisconsin

Medicare billing

Part B allowed, 2024
$4,301
Medicare patients
34
Services billed
44

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Bupropion XlBupropion Hcl22$655
Lamotrigine33$643
Escitalopram Oxalate43$631
Quetiapine Fumarate29$599
Duloxetine Hcl13$516
Clonazepam70$494
Trazodone Hcl38$430
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine18$378
Sertraline Hcl20$258
Venlafaxine Hcl ErVenlafaxine Hcl12$235
Eszopiclone26$227
Lorazepam21$219
Zolpidem Tartrate33$193
Fluoxetine Hcl21$167
Divalproex Sodium13$166

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Almatica Pharma LLCSertraline Hcl$22$25820 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 543 psychiatry providers in Wisconsin.

Other psychiatry in Madison

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →